Cod-DcDA (Cod-DcDA)
Recruiting
- Conditions
- advanced cancer
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- Patients 18 years of age or older with advanced cancer undergoing chemotherapy, receiving palliative care, or being treated in a hospice.
- Patients who have given their free written consent to participate in this study after obtaining full informed consent.
- Patients with an ECOG-PS of 0 to 2
- Patients without severe allergic diseases (including severe asthma, urticaria, angioedema, chronic allergic rhinitis of long standing, etc.)
- Patients who are expected to survive for at least 3 months
- Patients who are able to eat and drink on their own (patients who do not require assistance or support)
Exclusion Criteria
- Patients who are unable to perform swallowing exercises.
- Patients with cancer who have a treatment plan other than chemotherapy (surgery, radiotherapy, etc.) from 28 days prior to the start of this study to the end of the study.
- Patients who are judged by the principal investigator or subinvestigator to be inappropriate to participate in this study.
Study & Design
- Study Type
- Interventional
- Study Design
- single assignment
- Primary Outcome Measures
Name Time Method - Appetite suppression effect
- Secondary Outcome Measures
Name Time Method Occurrence of nausea and vomiting 24-120 hours after completion of chemotherapy Occurrence of nausea and vomiting 24-120 hours after completion of chemotherapy, use of antiemetic drugs (rescue drugs)
Inhibition of appetite loss Day 15 and Day 22 Inhibition of appetite loss at Day 15 and Day 22 in patients receiving palliative care or being treated in a hospice.
Nausea and vomiting Day15 and Day22 Nausea and vomiting at Day15 and Day22
Malaise Day15 and Day22 Malaise at Day15 and Day22
Percentage increase or decrease in food intake compared to Baseline Percentage increase or decrease in food intake compared to Baseline
Percentage change in skin blood flow (improvement in blood flow) Percentage change in skin blood flow (improvement in blood flow) if study subjects are advanced cancer patients receiving chemotherapy
Bowel movements (improvement in frequency of bowel movements, etc.) Bowel movements (improvement in frequency of bowel movements, etc.)